Physician profile
Alyssa Filliben
NPI 1235653833
$4,853.00
in general payments reported to CMS, 2019-2025
26 companies · $570 in 2025
The $570 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,463 · 2022: $1,320 · 2023: $622 · 2024: $878 · 2025: $570.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,070.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,070.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $1,961.54 | 2021-2025 | Watchman Flx, Watchman Access System |
| Amgen INC. | $641.54 | 2021-2024 | Repatha |
| Abbott Laboratories | $263.76 | 2021-2023 | Mitraclip |
| Janssen Pharmaceuticals, INC | $261.23 | 2021 | |
| Pfizer INC. | $227.20 | 2021-2025 | |
| Atricure, INC. | $190.70 | 2023-2024 | |
| Cleerly, INC. | $185.43 | 2025 | Cleerly Labs, Cleerly Ischemia |
| Merck Sharp & Dohme LLC | $161.53 | 2021-2022 | |
| Zoll Circulation INC | $138.50 | 2021 | |
| Osprey Medical INC | $116.27 | 2021 | |
| Medtronic, INC. | $100.77 | 2025 | Corevalve Evolut R |
| Astrazeneca Pharmaceuticals LP | $99.54 | 2024-2025 | Wainua, Farxiga |
| Novartis Pharmaceuticals Corporation | $77.94 | 2021-2023 | |
| Cvrx, INC. | $76.71 | 2024 | Barostim Neo System |
| Sanofi-Aventis U.S. LLC | $41.32 | 2023 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $41.11 | 2022-2023 | Camzyos |
| Abiomed | $36.42 | 2025 | |
| Actelion Pharmaceuticals US, INC. | $34.00 | 2024 | Opsumit, Uptravi |
| Bridgebio Pharma, INC. | $33.38 | 2025 | Attruby |
| Bayer Healthcare Pharmaceuticals INC. | $28.39 | 2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $27.32 | 2024 | Lifevest |
| Lexicon Pharmaceuticals, INC. | $23.70 | 2023 | Inpefa |
| Impulse Dynamics (USA) INC. | $23.57 | 2024 | Optimizer |
| Kestra Medical Technology Services, INC. | $22.82 | 2025 | Assure Wcd |
| Daiichi Sankyo INC. | $19.78 | 2022 | |
| Chiesi USA, INC. | $18.53 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alyssa Filliben listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.